|Mr. Elias Vamvakas||Exec. Chairman & Sec.||230.43k||N/A||1959|
|Mr. Joseph S. Jensen||CEO & Director||738.1k||N/A||1972|
|Mr. Michael Marquez||Chief Financial Officer||386.43k||N/A||1982|
|Dr. Benjamin Sullivan Ph.D.||Chief Scientific Officer||N/A||N/A||1976|
|Mr. Sam Fakhoury||VP of Quality, Compliance & Supply Chain||N/A||N/A||N/A|
TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.
TearLab Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.